Researchers at the University of California, Santa Cruz (UCSC) are developing a nanopore-based RNA liquid biopsy intended for early cancer detection. The work centers on validating the Locate-seq approach in esophageal precancer and cancer, supported by Oxford Nanopore Technologies. Nanopore RNA liquid biopsy refers to sequencing RNA signatures from bodily samples (often blood) to detect early disease-associated patterns without relying on tissue biopsies. The reported support suggests the platform’s feasibility is tied to established nanopore readout capabilities. If validation data translate into robust sensitivity and specificity, the approach could offer a scalable pathway for RNA-based screening or early detection use cases—particularly in cancers where symptoms appear late and tissue sampling is invasive.